Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MAIA Maia Biotechnology Inc

-0.21 (-8.64%)
Apr 12 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 178,852
Bid Price
Ask Price
News -
Day High 2.47


52 Week Range


Day Low 2.19
Company Name Stock Ticker Symbol Market Type
Maia Biotechnology Inc MAIA AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.21 -8.64% 2.22 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.47 2.19 2.47 2.205 2.43
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
767 178,852 $ 2.32 $ 414,779 - 0.82 - 4.2499
Last Trade Time Type Quantity Stock Price Currency
20:00:00 100 $ 2.205 USD

Maia Biotechnology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
31.27M 14.21M - 0 -19.77M -1.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Maia Biotechnology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MAIA Message Board. Create One! See More Posts on MAIA Message Board See More Message Board Posts

Historical MAIA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.272.622.192.49229,015-0.05-2.20%
1 Month1.343.071.312.30571,8920.8865.67%
3 Months1.,1370.9980.49%
6 Months2.533.070.821.69408,696-0.31-12.25%
1 Year3.724.24990.821.79240,446-1.50-40.32%
3 Years4.109.640.823.39230,755-1.88-45.85%
5 Years4.109.640.823.39230,755-1.88-45.85%

Maia Biotechnology Description

MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Your Recent History

Delayed Upgrade Clock